{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:58:57Z","timestamp":1793897937021,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of a safe and efficacious Zika virus (ZIKV) vaccine remains a global health priority. In our previous work, we developed an Adenovirus vectored ZIKV vaccine using a low-seroprevalent human Adenovirus type 4 (Ad4-prM-E) and compared it to an Ad5 vector (Ad5-prM-E). We found that vaccination with Ad4-prM-E leads to the development of a strong anti-ZIKV T-cell response without eliciting significant anti-ZIKV antibodies, while vaccination with Ad5-prM-E leads to the development of both anti-ZIKV antibody and T-cell responses in C57BL\/6 mice. However, both vectors conferred protection against ZIKV infection in a lethal challenge model. Here we continued to characterize the T-cell biased immune response observed in Ad4 immunized mice. Vaccination of BALB\/c mice resulted in immune correlates similar to C57BL\/6 mice, confirming that this response is not mouse strain-specific. Vaccination with an Ad4 expressing an influenza hemagglutinin (HA) protein resulted in anti-HA T-cell responses without the development of significant anti-HA antibodies, indicating this unique response is specific to the Ad4 serotype rather than the transgene expressed. Co-administration of a UV inactivated Ad4 vector with the Ad5-prM-E vaccine led to a significant reduction in anti-ZIKV antibody development suggesting that this serotype-specific immune profile is capsid-dependent. These results highlight the serotype-specific immune profiles elicited by different Adenovirus vector types and emphasize the importance of continued characterization of these alternative Ad serotypes.<\/jats:p>","DOI":"10.1038\/s41598-020-60238-5","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:04:32Z","timestamp":1582801472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Characterization of a Species E Adenovirus Vector as a Zika virus vaccine"],"prefix":"10.1038","volume":"10","author":[{"given":"Brianna L.","family":"Bullard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette N.","family":"Corder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-4348","authenticated-orcid":false,"given":"Theodore C.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5029-0662","authenticated-orcid":false,"given":"Eric A.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"60238_CR1","doi-asserted-by":"publisher","unstructured":"Shan, C. al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nature Communications 8, https:\/\/doi.org\/10.1038\/s41467-017-00737-8 (2017).","DOI":"10.1038\/s41467-017-00737-8"},{"key":"60238_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.chom.2018.09.008","volume":"24","author":"X Xie","year":"2018","unstructured":"Xie, X. et al. A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission. Cell Host & Microbe 24, 487\u2013499.e485, https:\/\/doi.org\/10.1016\/j.chom.2018.09.008 (2018).","journal-title":"Cell Host & Microbe"},{"key":"60238_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03337-2","volume":"9","author":"SS Kwek","year":"2018","unstructured":"Kwek, S. S. et al. A systematic approach to the development of a safe live attenuated Zika vaccine. Nature Communications 9, 1031, https:\/\/doi.org\/10.1038\/s41467-018-03337-2 (2018).","journal-title":"Nature Communications"},{"key":"60238_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478 (2016).","journal-title":"Nature"},{"issue":"10120","key":"60238_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","volume":"391","author":"Kayvon Modjarrad","year":"2018","unstructured":"Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet, https:\/\/doi.org\/10.1016\/S0140-6736(17)33106-9 (2017).","journal-title":"The Lancet"},{"key":"60238_CR6","doi-asserted-by":"publisher","unstructured":"Medina, L. O. et al. A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates. Frontiers in Immunology 9, https:\/\/doi.org\/10.3389\/fimmu.2018.02464 (2018).","DOI":"10.3389\/fimmu.2018.02464"},{"key":"60238_CR7","doi-asserted-by":"publisher","unstructured":"Tai, W. et al. Rational design of Zika virus subunit vaccine with enhanced efficacy. Journal of Virology, JVI.02187-02118, https:\/\/doi.org\/10.1128\/jvi.02187-18 (2019).","DOI":"10.1128\/jvi.02187-18"},{"key":"60238_CR8","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129\u20131132, https:\/\/doi.org\/10.1126\/science.aah6157 (2016).","journal-title":"Science"},{"key":"60238_CR9","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","volume":"16","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell reports 16, 1485\u20131491, https:\/\/doi.org\/10.1016\/j.celrep.2016.07.049 (2016).","journal-title":"Cell reports"},{"key":"60238_CR10","doi-asserted-by":"publisher","unstructured":"Tebas, P. et al. Safety and Immunogenicity of an Anti\u2013Zika Virus DNA Vaccine \u2014 Preliminary Report. New England Journal of Medicine, https:\/\/doi.org\/10.1056\/NEJMoa1708120 (2017).","DOI":"10.1056\/NEJMoa1708120"},{"key":"60238_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248\u2013251, https:\/\/doi.org\/10.1038\/nature21428 (2017).","journal-title":"Nature"},{"key":"60238_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 168, 1114\u20131125.e1110, https:\/\/doi.org\/10.1016\/j.cell.2017.02.017 (2017).","journal-title":"Cell"},{"key":"60238_CR13","doi-asserted-by":"publisher","unstructured":"N\u00fcrnberger, C., Bodmer, B. S., Fiedler, A. H., Gabriel, G. & M\u00fchlebach, M. D. A measles virus-based vaccine candidate mediates protection against Zika virus in an allogenic mouse pregnancy model. Journal of Virology, https:\/\/doi.org\/10.1128\/jvi.01485-18 (2018).","DOI":"10.1128\/jvi.01485-18"},{"key":"60238_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29401-x","volume":"8","author":"J Emanuel","year":"2018","unstructured":"Emanuel, J. et al. A VSV-based Zika virus vaccine protects mice from lethal challenge. Scientific Reports 8, 11043, https:\/\/doi.org\/10.1038\/s41598-018-29401-x (2018).","journal-title":"Scientific Reports"},{"key":"60238_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33105-7","author":"MR Gaudinski","year":"2017","unstructured":"Gaudinski, M. R. et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet, https:\/\/doi.org\/10.1016\/S0140-6736(17)33105-7 (2017).","journal-title":"Lancet"},{"key":"60238_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04859-5","volume":"9","author":"C L\u00f3pez-Camacho","year":"2018","unstructured":"L\u00f3pez-Camacho, C. et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nature Communications 9, 2441, https:\/\/doi.org\/10.1038\/s41467-018-04859-5 (2018).","journal-title":"Nature Communications"},{"key":"60238_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14891-y","volume":"7","author":"A Lingel","year":"2017","unstructured":"Lingel, A., Bullard, B. L. & Weaver, E. A. Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine. Scientific Reports 7, 14912, https:\/\/doi.org\/10.1038\/s41598-017-14891-y (2017).","journal-title":"Scientific Reports"},{"key":"60238_CR18","doi-asserted-by":"publisher","first-page":"e0140702","DOI":"10.1371\/journal.pone.0140702","volume":"10","author":"RJ Webby","year":"2015","unstructured":"Webby, R. J. & Weaver, E. A. Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses. PLoS One 10, e0140702, https:\/\/doi.org\/10.1371\/journal.pone.0140702 (2015).","journal-title":"PLoS One"},{"key":"60238_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/infdis\/jiu485","volume":"211","author":"LR Baden","year":"2015","unstructured":"Baden, L. R. et al. Induction of HIV-1\u2013Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans. The Journal of Infectious Diseases 211, 518\u2013528, https:\/\/doi.org\/10.1093\/infdis\/jiu485 (2015).","journal-title":"The Journal of Infectious Diseases"},{"key":"60238_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/infdis\/jis671","volume":"207","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). The Journal of Infectious Diseases 207, 248\u2013256, https:\/\/doi.org\/10.1093\/infdis\/jis671 (2013).","journal-title":"The Journal of Infectious Diseases"},{"key":"60238_CR21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1586\/14760584.2015.1083429","volume":"14","author":"FJD Mennechet","year":"2015","unstructured":"Mennechet, F. J. D., Tran, T. T. P., Eichholz, K., van de Perre, P. & Kremer, E. J. Ebola virus vaccine: benefit and risks of adenovirus-based vectors. Expert Review of Vaccines 14, 1471\u20131478, https:\/\/doi.org\/10.1586\/14760584.2015.1083429 (2015).","journal-title":"Expert Review of Vaccines"},{"key":"60238_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","volume":"29","author":"JE Ledgerwood","year":"2010","unstructured":"Ledgerwood, J. E. et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29, 304\u2013313, https:\/\/doi.org\/10.1016\/j.vaccine.2010.10.037 (2010).","journal-title":"Vaccine"},{"key":"60238_CR23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood, J. E. et al. Chimpanzee Adenovirus Vector Ebola Vaccine. New England Journal of Medicine 376, 928\u2013938, https:\/\/doi.org\/10.1056\/NEJMoa1410863 (2017).","journal-title":"New England Journal of Medicine"},{"key":"60238_CR24","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.4161\/hv.29594","volume":"10","author":"H Fausther-Bovendo","year":"2014","unstructured":"Fausther-Bovendo, H. & Kobinger, G. P. Pre-existing immunity against Ad vectors. Human Vaccines & Immunotherapeutics 10, 2875\u20132884, https:\/\/doi.org\/10.4161\/hv.29594 (2014).","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"3","key":"60238_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/infdis\/jiy187","volume":"218","author":"Qiang Guo","year":"2018","unstructured":"Guo, Q. et al. Immunization with a Novel Human type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models. The Journal of Infectious Diseases, jiy187\u2013jiy187, https:\/\/doi.org\/10.1093\/infdis\/jiy187 (2018).","journal-title":"The Journal of Infectious Diseases"},{"key":"60238_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ebiom.2016.09.028","volume":"13","author":"E Kim","year":"2016","unstructured":"Kim, E. et al. Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation. EBioMedicine 13, 315\u2013320, https:\/\/doi.org\/10.1016\/j.ebiom.2016.09.028 (2016).","journal-title":"EBioMedicine"},{"key":"60238_CR27","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.7150\/thno.35919","volume":"9","author":"H-H Lin","year":"2019","unstructured":"Lin, H.-H. et al. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization. Theranostics 9, 4811\u20134826, https:\/\/doi.org\/10.7150\/thno.35919 (2019).","journal-title":"Theranostics"},{"key":"60238_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0072-6","volume":"3","author":"X Liu","year":"2018","unstructured":"Liu, X. et al. Incorporation of NS1 and prM\/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein. npj Vaccines 3, 29, https:\/\/doi.org\/10.1038\/s41541-018-0072-6 (2018).","journal-title":"npj Vaccines"},{"key":"60238_CR29","doi-asserted-by":"publisher","first-page":"eaao4163","DOI":"10.1126\/scitranslmed.aao4163","volume":"9","author":"P Abbink","year":"2017","unstructured":"Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Science translational medicine 9, eaao4163 (2017).","journal-title":"Science translational medicine"},{"key":"60238_CR30","doi-asserted-by":"publisher","first-page":"e0202820","DOI":"10.1371\/journal.pone.0202820","volume":"13","author":"F Cox","year":"2018","unstructured":"Cox, F. et al. Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLOS One 13, e0202820, https:\/\/doi.org\/10.1371\/journal.pone.0202820 (2018).","journal-title":"PLOS One"},{"key":"60238_CR31","doi-asserted-by":"publisher","unstructured":"Xu, K. et al. Recombinant Chimpanzee Adenovirus Vaccine AdC7-M\/E Protects against Zika Virus Infection and Testis Damage. J. Virol. 92, https:\/\/doi.org\/10.1128\/JVI.01722-17 (2018).","DOI":"10.1128\/JVI.01722-17"},{"key":"60238_CR32","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.celrep.2019.08.005","volume":"28","author":"AO Hassan","year":"2019","unstructured":"Hassan, A. O. et al. A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy. Cell Reports 28, 2634\u20132646.e2634, https:\/\/doi.org\/10.1016\/j.celrep.2019.08.005 (2019).","journal-title":"Cell Reports"},{"key":"60238_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35755-z","volume":"8","author":"BL Bullard","year":"2018","unstructured":"Bullard, B. L., Corder, B. N., Gorman, M. J., Diamond, M. S. & Weaver, E. A. Efficacy of a T Cell-Biased Adenovirus Vector as a Zika Virus Vaccine. Scientific Reports 8, 18017, https:\/\/doi.org\/10.1038\/s41598-018-35755-z (2018).","journal-title":"Scientific Reports"},{"key":"60238_CR34","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/intimm\/dxl102","volume":"18","author":"J Yagi","year":"2006","unstructured":"Yagi, J. et al. Genetic background influences Th cell differentiation by controlling the capacity for IL-2-induced IL-4 production by naive CD4+ T cells. International Immunology 18, 1681\u20131690, https:\/\/doi.org\/10.1093\/intimm\/dxl102 (2006).","journal-title":"International Immunology"},{"key":"60238_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","volume":"22","author":"H Watanabe","year":"2004","unstructured":"Watanabe, H., Numata, K., Ito, T., Takagi, K. & Matsukawa, A. Innate immune response in Th1-and Th2-dominant mouse strains. Shock 22, 460\u2013466 (2004).","journal-title":"Shock"},{"key":"60238_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","volume":"354","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Rapid Development of a DNA Vaccine for Zika Virus. Science (New York, N.Y.) 354, 237\u2013240, https:\/\/doi.org\/10.1126\/science.aai9137 (2016).","journal-title":"Science (New York, N.Y.)"},{"key":"60238_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.chom.2016.12.010","volume":"21","author":"A Elong Ngono","year":"2017","unstructured":"Elong Ngono, A. et al. Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice. Cell Host Microbe 21, 35\u201346, https:\/\/doi.org\/10.1016\/j.chom.2016.12.010 (2017).","journal-title":"Cell Host Microbe"},{"key":"60238_CR38","doi-asserted-by":"publisher","first-page":"e00900","DOI":"10.1128\/JVI.00900-17","volume":"91","author":"H Huang","year":"2017","unstructured":"Huang, H. et al. CD8(+) T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection. Journal of virology 91, e00900\u201300917, https:\/\/doi.org\/10.1128\/JVI.00900-17 (2017).","journal-title":"Journal of virology"},{"key":"60238_CR39","doi-asserted-by":"publisher","first-page":"e1006184","DOI":"10.1371\/journal.ppat.1006184","volume":"13","author":"RD Pardy","year":"2017","unstructured":"Pardy, R. D. et al. Analysis of the T Cell Response to Zika Virus and Identification of a Novel CD8+ T Cell Epitope in Immunocompetent Mice. PLoS pathogens 13, e1006184\u2013e1006184, https:\/\/doi.org\/10.1371\/journal.ppat.1006184 (2017).","journal-title":"PLoS pathogens"},{"key":"60238_CR40","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/21645515.2015.1016674","volume":"11","author":"K Xiang","year":"2015","unstructured":"Xiang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. Human Vaccines & Immunotherapeutics 11, 1209\u20131222, https:\/\/doi.org\/10.1080\/21645515.2015.1016674 (2015).","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"60238_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2018.09.009","volume":"159","author":"MS Mehand","year":"2018","unstructured":"Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antiviral Research 159, 63\u201367, https:\/\/doi.org\/10.1016\/j.antiviral.2018.09.009 (2018).","journal-title":"Antiviral Research"},{"key":"60238_CR42","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1128\/AEM.03457-12","volume":"79","author":"F Bosshard","year":"2013","unstructured":"Bosshard, F., Armand, F., Hamelin, R. & Kohn, T. Mechanisms of human adenovirus inactivation by sunlight and UVC light as examined by quantitative PCR and quantitative proteomics. Appl Environ Microbiol 79, 1325\u20131332, https:\/\/doi.org\/10.1128\/AEM.03457-12 (2013).","journal-title":"Appl Environ Microbiol"},{"key":"60238_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.virol.2008.01.017","volume":"374","author":"ZC Hartman","year":"2008","unstructured":"Hartman, Z. C. et al. Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology 374, 453\u2013467, https:\/\/doi.org\/10.1016\/j.virol.2008.01.017 (2008).","journal-title":"Virology"},{"key":"60238_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/sj.mt.6300024","volume":"15","author":"SE Hensley","year":"2007","unstructured":"Hensley, S. E. et al. Type I Interferon Inhibits Antibody Responses Induced by a Chimpanzee Adenovirus Vector. Molecular Therapy 15, 393\u2013403, https:\/\/doi.org\/10.1038\/sj.mt.6300024 (2007).","journal-title":"Molecular Therapy"},{"issue":"12","key":"60238_CR45","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/gt.2008.18","volume":"15","author":"D M Appledorn","year":"2008","unstructured":"Appledorn, D. M. et al. Wild-type adenoviruses from groups A\u2013F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Therapy 15, 885, https:\/\/doi.org\/10.1038\/gt.2008.18 https:\/\/www.nature.com\/articles\/gt200818#supplementary-information (2008).","journal-title":"Gene Therapy"},{"key":"60238_CR46","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1128\/JVI.02696-06","volume":"81","author":"P Abbink","year":"2007","unstructured":"Abbink, P. et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of virology 81, 4654\u20134663, https:\/\/doi.org\/10.1128\/JVI.02696-06 (2007).","journal-title":"Journal of virology"},{"key":"60238_CR47","doi-asserted-by":"publisher","first-page":"9590","DOI":"10.1128\/JVI.00740-12","volume":"86","author":"JE Teigler","year":"2012","unstructured":"Teigler, J. E., Iampietro, M. J. & Barouch, D. H. Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys. Journal of Virology 86, 9590\u20139598, https:\/\/doi.org\/10.1128\/JVI.00740-12 (2012).","journal-title":"Journal of Virology"},{"key":"60238_CR48","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4161\/hv.27238","volume":"10","author":"EA Weaver","year":"2014","unstructured":"Weaver, E. A. Vaccines within vaccines: The use of adenovirus types 4 and 7 as influenza vaccine vectors. Human Vaccines & Immunotherapeutics 10, 544\u2013556, https:\/\/doi.org\/10.4161\/hv.27238 (2014).","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"60238_CR49","doi-asserted-by":"publisher","first-page":"e18314","DOI":"10.1371\/journal.pone.0018314","volume":"6","author":"EA Weaver","year":"2011","unstructured":"Weaver, E. A., Rubrum, A. M., Webby, R. J. & Barry, M. A. Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin. PLoS One 6, e18314, https:\/\/doi.org\/10.1371\/journal.pone.0018314 (2011).","journal-title":"PLoS One"},{"key":"60238_CR50","doi-asserted-by":"publisher","first-page":"e1002111","DOI":"10.1371\/journal.ppat.1002111","volume":"7","author":"KA Dowd","year":"2011","unstructured":"Dowd, K. A., Jost, C. A., Durbin, A. P., Whitehead, S. S. & Pierson, T. C. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS pathogens 7, e1002111\u2013e1002111, https:\/\/doi.org\/10.1371\/journal.ppat.1002111 (2011).","journal-title":"PLoS pathogens"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60238-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60238-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:16:51Z","timestamp":1670311011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60238-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60238"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60238-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"20 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3613"}}